Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. - Wikidata - awgldk - TriplyDB

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

http://www.wikidata.org/entity/Q34804865

about

Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes.Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent Metformin based dual-combination therapies in drug naïve type 2 diabetic patients.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

P2860

Q30846870-C4752F6D-6591-483A-A33F-60F8C5648F91 Q34419202-83B39C6A-37DC-44B7-B97A-D5BBAAA9FE69 Q34824247-CE41D09E-214E-4E56-ACEF-F79FBC79E1B9 Q35661969-3B88F82B-2399-456A-BA1A-7A9CCB48B191 Q36192977-C0E35908-FC0E-4800-8F57-9420996D4E6F Q37435700-BD010C46-59CE-491A-B75E-A0DE927EE61C Q38258278-405BD384-34DC-4A87-B54E-3ABB9933E6A9 Q38263364-015752ED-63C3-458E-8E50-F62B4A8837E3 Q38497122-85C46043-887E-4D53-A372-659D73F664D4 Q38638523-310654FC-2B04-4861-ABC6-88FF81D35951 Q38762377-906F2AC6-D7BA-45F5-BEF0-D3C9A210874B Q47386188-1469DDE2-7319-48BA-97C4-9DB08937DC50

P2860

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

http://www.wikidata.org/entity/Q34804865

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Initial combination of linagli ...... -blind 1-year extension study.

@ast

Initial combination of linagli ...... -blind 1-year extension study.

@en

Initial combination of linagli ...... -blind 1-year extension study.

@nl

type

label

Initial combination of linagli ...... -blind 1-year extension study.

@ast

Initial combination of linagli ...... -blind 1-year extension study.

@en

Initial combination of linagli ...... -blind 1-year extension study.

@nl

prefLabel

Initial combination of linagli ...... -blind 1-year extension study.

@ast

Initial combination of linagli ...... -blind 1-year extension study.

@en

Initial combination of linagli ...... -blind 1-year extension study.

@nl

P1433

Q34804865-4FBCBC99-DECC-469F-A7EB-D79268A53E4F

P1476

Q34804865-98FADCCC-4677-41C9-8C63-CD4CD21326B7

P2093

Q34804865-0E35898E-D06F-4349-8722-3EB0830A5A46

Q34804865-611C3B27-2034-4BC7-ABD9-68DEBF4D4D7D

Q34804865-CC6BB53B-B53A-4EAD-9D1D-791D0DC6A2D7

Q34804865-DC00202E-6E8D-4029-BCC8-52DB603CACD4

Q34804865-F83AE38E-0AD7-4825-AB03-9AE511983393

Q34804865-FB25F674-060D-43C8-B918-A1B60E196749

P2860

Q34804865-07FA0D7C-B11B-4300-84B2-A149AAD760D3

Q34804865-226EA844-FD1B-4F26-8628-4A980E11C626

Q34804865-3687C591-8F88-4BAD-A64F-12E83AD43C3F

Q34804865-4F6738BD-2391-4864-AB7F-8BC01A30BA38

Q34804865-B17B21E2-DED0-41BB-BF4F-F4AAAEF1C917

Q34804865-D3FBAEED-65D1-4093-AA23-FDD7D4FF0368

Q34804865-E11F9466-FE10-40D9-A427-8841000691DF

Q34804865-E42707E8-7047-4AF4-811C-662B8FD3D3A8

Q34804865-EA344505-C4D4-4B23-8937-EFB13F4B2A39

Q34804865-F485BCD2-8D86-4849-B61E-071A6C81905E

P304

Q34804865-63490E00-D442-4E40-B4B2-B98BAB85CEF0

P31

Q34804865-BE7274D9-6705-48C3-8F7D-7440719ED02D

P356

Q34804865-76C832D0-55AD-4FDC-9206-A87E3749A77D

P433

Q34804865-72E81731-51FA-48F8-9559-E0B9A113F8BA

P478

Q34804865-09222728-9CB4-4707-8457-387F1334B813

P577

Q34804865-F93DB50A-BA85-4277-8BAF-0409331F4B58

P5875

Q34804865-F9FF5897-51B9-4FEE-9033-ACEF22196307

P698

Q34804865-3A7DB485-FD62-4AC7-96FD-6725C0ECB179

P921

Q34804865-B05B0CD2-599D-4CD2-B193-8E1ACB270F41

Q34804865-D1325074-FA91-479B-AAC2-6C3686A55472

P932

Q34804865-580EC607-CF5B-43B9-8A35-39DBEDE99747

P356

P1433

International Journal of Clinical Practice

P1476

Initial combination of linagli ...... -blind 1-year extension study.

@en

P2093

H-J Woerle

http://www.w3.org/2001/XMLSchema#string

M von Eynatten

http://www.w3.org/2001/XMLSchema#string

R Jones

http://www.w3.org/2001/XMLSchema#string

S Weber

http://www.w3.org/2001/XMLSchema#string

T Haak

http://www.w3.org/2001/XMLSchema#string

T Meinicke

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record.

Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

P304

1283-1293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12308

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257751717

http://www.w3.org/2001/XMLSchema#string

P698

24118640

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4282285

http://www.w3.org/2001/XMLSchema#string